OLIGONUCLEOTIDES FOR DGAT2 MODULATION

This disclosure relates to novel DGAT2 targeting sequences. Novel DGAT2 targeting oligonucleotides for the treatment of non-alcoholic fatty liver disease (NAFLD) and lipodystrophy syndromes (or metabolic syndrome) are also provided. La divulgation concerne de nouvelles séquences de ciblage de DGAT2....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YENILMEZ, Batuhan Orbay, CZECH, Michael P, KHVOROVA, Anastasia
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This disclosure relates to novel DGAT2 targeting sequences. Novel DGAT2 targeting oligonucleotides for the treatment of non-alcoholic fatty liver disease (NAFLD) and lipodystrophy syndromes (or metabolic syndrome) are also provided. La divulgation concerne de nouvelles séquences de ciblage de DGAT2. La divulgation concerne également de nouveaux oligonucléotides ciblant le DGAT2 pour le traitement de la stéatose hépatique non alcoolique (NAFLD) et de syndromes lipodystrophiques (ou syndrome métabolique).